Virtus ETF Advisers’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-9,448
| Closed | -$330K | – | 603 |
|
|
2024
Q4 | $330K | Buy |
9,448
+1,439
| +18% | +$53.8K | 0.13% | 228 |
|
|
2024
Q3 | $321K | Hold |
8,009
| – | – | 0.15% | 226 |
|
|
2024
Q2 | $382K | Buy |
8,009
+361
| +5% | +$14.8K | 0.19% | 185 |
|
|
2024
Q1 | $332K | Buy |
7,648
+1,100
| +17% | +$52.4K | 0.18% | 220 |
|
|
2023
Q4 | $331K | Sell |
6,548
-909
| -12% | -$43.5K | 0.21% | 205 |
|
|
2023
Q3 | $338K | Sell |
7,457
-961
| -11% | -$39.6K | 0.21% | 194 |
|
|
2023
Q2 | $345K | Buy |
8,418
+374
| +5% | +$14.4K | 0.2% | 156 |
|
|
2023
Q1 | $287K | Buy |
8,044
+144
| +2% | +$5.41K | 0.16% | 242 |
|
|
2022
Q4 | $298K | Buy |
7,900
+871
| +12% | +$36.6K | 0.16% | 268 |
|
|
2022
Q3 | $311K | Buy |
7,029
+104
| +2% | +$4.38K | 0.12% | 271 |
|
|
2022
Q2 | $256K | Sell |
6,925
-5,371
| -44% | -$203K | 0.09% | 292 |
|
|
2022
Q1 | $455K | Hold |
12,296
| – | – | 0.2% | 136 |
|
|
2021
Q4 | $374K | Buy |
12,296
+194
| +2% | +$6.11K | 0.14% | 173 |
|
|
2021
Q3 | $406K | Sell |
12,102
-1,110
| -8% | -$41.8K | 0.18% | 170 |
|
|
2021
Q2 | $527K | Buy |
13,212
+128
| +1% | +$5.01K | 0.22% | 131 |
|
|
2021
Q1 | $588K | Buy |
13,084
+359
| +3% | +$20K | 0.25% | 129 |
|
|
2020
Q4 | $719K | Buy |
12,725
+2,712
| +27% | +$135K | 0.3% | 94 |
|
|
2020
Q3 | $475K | Buy |
10,013
+843
| +9% | +$46.8K | 0.25% | 143 |
|
|
2020
Q2 | $541K | Sell |
9,170
-159
| -2% | -$8.85K | 0.26% | 140 |
|
|
2020
Q1 | $441K | Sell |
9,329
-787
| -8% | -$43.9K | 0.18% | 183 |
|
|
2019
Q4 | $611K | Sell |
10,116
-1,040
| -9% | -$62K | 0.1% | 186 |
|
|
2019
Q3 | $668K | Sell |
11,156
-1,881
| -14% | -$123K | 0.13% | 167 |
|
|
2019
Q2 | $838K | Buy |
+13,037
| New | +$922K | 0.18% | 175 |
|
|
2019
Q1 | – | Sell |
-11,369
| Closed | -$615K | – | 200 |
|
|
2018
Q4 | $615K | Sell |
11,369
-5,163
| -31% | -$263K | 0.11% | 40 |
|
|
2018
Q3 | $853K | Buy |
16,532
+1,114
| +7% | +$52.3K | 0.09% | 61 |
|
|
2018
Q2 | $642K | Sell |
15,418
-2,164
| -12% | -$95.9K | 0.57% | 125 |
|
|
2018
Q1 | $775K | Sell |
17,582
-1,028
| -6% | -$52.2K | 0.67% | 77 |
|
|
2017
Q4 | $936K | Sell |
18,610
-1,765
| -9% | -$96.8K | 1.17% | 38 |
|
|
2017
Q3 | $1.03M | Hold |
20,375
| – | – | 0.14% | 57 |
|
|
2017
Q2 | $1.04M | Sell |
20,375
-1,506
| -7% | -$70.1K | 0.15% | 60 |
|
|
2017
Q1 | $880K | Buy |
21,881
+2,104
| +11% | +$94.5K | 0.16% | 75 |
|
|
2016
Q4 | $946K | Sell |
19,777
-8,079
| -29% | -$320K | 0.28% | 59 |
|
|
2016
Q3 | $1.02M | Buy |
27,856
+3,511
| +14% | +$110K | 0.49% | 34 |
|
|
2016
Q2 | $567K | Buy |
24,345
+13,898
| +133% | +$448K | 0.42% | 31 |
|
|
2016
Q1 | $423K | Hold |
10,447
| – | – | 0.58% | 47 |
|
|
2015
Q4 | $647K | Buy |
+10,447
| New | +$564K | 1.78% | 13 |
|
Other funds holding IONS
BG
DTC
Virtus ETF Advisers's IONS Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 9,448 shares — an estimated $330K sold.
Virtus ETF Advisers first reported a position in IONS in Q4 2015 and held it in 36 quarters. The position peaked at $1.04M in Q2 2017. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.
- Virtus ETF Advisers reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 9,448 Ionis Pharmaceuticals shares in Q1 2025, an estimated $330K.
- Virtus ETF Advisers first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 36 quarters.
- Virtus ETF Advisers's Ionis Pharmaceuticals position peaked at $1.04M in Q2 2017.
- 343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.